Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$2.00 -0.07 (-3.38%)
As of 02/03/2023 15:59:53 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.